Enanta Pharmaceuticals (ENTA) Current Assets (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Current Assets came in at $178.4 million in Q1 2026, down 26.54% YoY from $242.9 million in Q1 2025, and down 10.2% on a QoQ basis from $198.7 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Current Assets (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Current Assets data on file, last reported at $178.4 million in Q1 2026.
- Quarterly Current Assets fell 26.54% year-over-year to $178.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.4 million (down 26.54% YoY) and the FY2025 annual result came in at $204.3 million, down 31.85% from the prior year.
- Current Assets fell to $178.4 million in Q1 2026, from $198.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $448.5 million in Q2 2023 to a low of $178.4 million in Q1 2026.
- A 5-year average of $296.2 million and a median of $286.6 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets surged 43.26% — and 2024, when it sank 36.1%.
- Tracing ENTA's Current Assets over 5 years: stood at $283.7 million in 2022, then soared by 37.57% to $390.3 million in 2023, then slumped by 31.3% to $268.1 million in 2024, then fell by 25.9% to $198.7 million in 2025, then declined by 10.2% to $178.4 million in 2026.
- The last three Current Assets figures came in at $178.4 million (Q1 2026), $198.7 million (Q4 2025), and $204.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 203.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 203.62 Mn |
| Mar 31, 2026 | 178.41 Mn |
| Dec 31, 2025 | 198.68 Mn |
| Sep 30, 2025 | 204.34 Mn |
| Jun 30, 2025 | 222.71 Mn |
| Mar 31, 2025 | 242.86 Mn |
| Dec 31, 2024 | 268.15 Mn |
| Sep 30, 2024 | 299.85 Mn |
| Jun 30, 2024 | 286.58 Mn |
| Mar 31, 2024 | 351.03 Mn |
| Dec 31, 2023 | 390.30 Mn |
| Sep 30, 2023 | 422.79 Mn |
| Jun 30, 2023 | 448.47 Mn |
| Mar 31, 2023 | 271.14 Mn |
| Dec 31, 2022 | 283.70 Mn |
| Sep 30, 2022 | 311.71 Mn |
| Jun 30, 2022 | 313.04 Mn |
| Mar 31, 2022 | 341.87 Mn |
| Dec 31, 2021 | 326.96 Mn |
| Sep 30, 2021 | 319.02 Mn |